Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALRN Aileron Therapeutics		$2.52	$1.61 ▼ $4.40	$45.72M	2.24	82,980 shs	63,385 shs
TIL Instil Bio	$26.51 +4.7%	$27.07	$10.80 ▼ $92.00	$178.94M	2.16	193,664 shs	65,924 shs
TVGN Tevogen Bio	$0.90 -1.6%	$1.12	$0.26 ▼ $3.09	$166.31M	-0.77	1.42 million shs	216,854 shs
VYGR Voyager Therapeutics	$3.36 +0.3%	$3.26	$2.64 ▼ $8.27	$186.38M	0.9	529,485 shs	432,491 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALRN Aileron Therapeutics	0.00%	0.00%	0.00%	0.00%	-12.08%
TIL Instil Bio	-0.67%	-6.08%	-8.29%	+2.93%	+118.17%
TVGN Tevogen Bio	-1.25%	-9.00%	-20.08%	-25.28%	+48.91%
VYGR Voyager Therapeutics	-5.90%	-8.22%	+5.68%	+12.04%	-51.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	3.0597 of 5 stars	3.5	4.0	0.0	0.0	0.8	3.3	0.6
TVGN Tevogen Bio	3.9436 of 5 stars	3.5	3.0	0.0	0.0	3.1	2.5	0.0
VYGR Voyager Therapeutics	3.5592 of 5 stars	3.6	1.0	0.0	4.6	0.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALRN Aileron Therapeutics	0.00	N/A	N/A	N/A
TIL Instil Bio	3.00	Buy	$119.00	348.89% Upside
TVGN Tevogen Bio	3.00	Buy	$10.00	1,005.71% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.25	294.26% Upside

Current Analyst Ratings Breakdown

Latest ALRN, VYGR, TIL, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/15/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
8/7/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
8/4/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/27/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	$1.41 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$19.50 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($0.10) per share	N/A
VYGR Voyager Therapeutics	$80M	2.33	N/A	N/A	$4.40 per share	0.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALRN Aileron Therapeutics	-$15.73M	-$3.12	0.00	N/A	N/A	N/A	-74.08%	-27.93%	N/A
TIL Instil Bio	-$74.14M	-$12.92	N/A	N/A	N/A	N/A	-54.32%	-33.65%	N/A
TVGN Tevogen Bio	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-775.49%	N/A
VYGR Voyager Therapeutics	-$65M	-$1.85	N/A	N/A	N/A	-253.49%	-37.65%	-28.89%	N/A

Latest ALRN, VYGR, TIL, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	N/A	TVGN Tevogen Bio	-$0.05	-$0.03	+$0.02	-$0.03	N/A	N/A
8/13/2025	Q2 2025	TIL Instil Bio	-$1.72	-$3.24	-$1.52	-$3.24	N/A	N/A
8/6/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$9.50 million	$5.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALRN Aileron Therapeutics	N/A	3.30	3.30
TIL Instil Bio	0.64	14.97	14.97
TVGN Tevogen Bio	N/A	0.26	0.35
VYGR Voyager Therapeutics	N/A	5.43	5.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALRN Aileron Therapeutics	90.89%
TIL Instil Bio	60.56%
TVGN Tevogen Bio	N/A
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ALRN Aileron Therapeutics	5.10%
TIL Instil Bio	47.20%
TVGN Tevogen Bio	73.24%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALRN Aileron Therapeutics	9	21.67 million	20.56 million	Not Optionable
TIL Instil Bio	410	6.75 million	3.57 million	No Data
TVGN Tevogen Bio	3	183.89 million	49.21 million	N/A
VYGR Voyager Therapeutics	100	55.47 million	51.93 million	Optionable

ALRN, VYGR, TIL, and TVGN Headlines

Recent News About These Companies

Voyager Therapeutics Extends Cash Runway to 2028

August 13, 2025 | msn.com

Research Analysts Offer Predictions for VYGR Q3 Earnings

August 12, 2025 | americanbankingnews.com

Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

August 11, 2025 | theglobeandmail.com

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

August 11, 2025 | theglobeandmail.com

Equities Analysts Offer Predictions for VYGR Q3 Earnings

August 11, 2025 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Estimates By $0.09 EPS

August 10, 2025 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Given New $8.00 Price Target at Wedbush

August 10, 2025 | americanbankingnews.com

Voyager Therapeutics (VYGR) Receives a Buy from Canaccord Genuity

August 9, 2025 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Price Target Lowered to $8.00 at Wedbush

August 8, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Voyager Reports Second Quarter 2025 Financial and Operating Results

August 6, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Buy" by Analysts

July 30, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

Voyager 1 and 2: From Earth to Interstellar Space: The Final Frontier Awaits

July 21, 2025 | msn.com

Read the NASA ‘Voyager Declaration’ Letter of Dissent

July 21, 2025 | nytimes.com

Mascarene Partners Acquires Voyager Trucking

July 18, 2025 | finance.yahoo.com

Voyager Therapeutics adds new gene therapy to Alzheimer’s program

July 18, 2025 | bioworld.comB

Mascarene buys US waste services company Voyager Trucking

July 18, 2025 | realassets.ipe.comR

Mascarene to acquire waste services transport firm Voyager Trucking Corporation

July 18, 2025 | pehub.com

Looking Beyond Voyager 1 And 2

July 17, 2025 | msn.com

Robert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of Voyager

July 16, 2025 | fandomwire.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALRN, VYGR, TIL, and TVGN Company Descriptions

Aileron Therapeutics NASDAQ:ALRN

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Instil Bio NASDAQ:TIL

$26.51 +1.18 (+4.66%)

Closing price 04:00 PM Eastern

Extended Trading

$25.82 -0.69 (-2.58%)

As of 04:54 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Tevogen Bio NASDAQ:TVGN

$0.90 -0.01 (-1.60%)

Closing price 04:00 PM Eastern

Extended Trading

$0.91 +0.01 (+0.95%)

As of 04:40 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Voyager Therapeutics NASDAQ:VYGR

$3.36 +0.01 (+0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$3.36 +0.01 (+0.15%)

As of 04:20 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time